73.54
1.55%
1.12
After Hours:
74.25
0.71
+0.97%
Intra Cellular Therapies Inc stock is traded at $73.54, with a volume of 839.59K.
It is up +1.55% in the last 24 hours and down -5.92% over the past month.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
See More
Previous Close:
$72.42
Open:
$74.89
24h Volume:
839.59K
Relative Volume:
0.85
Market Cap:
$7.77B
Revenue:
$563.44M
Net Income/Loss:
$-84.30M
P/E Ratio:
-45.68
EPS:
-1.61
Net Cash Flow:
$-61.23M
1W Performance:
+0.35%
1M Performance:
-5.92%
6M Performance:
+11.37%
1Y Performance:
+27.98%
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Name
Intra Cellular Therapies Inc
Sector
Phone
212-923-3344
Address
430 EAST 29TH STREET, NEW YORK, NY
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-03-24 | Initiated | Robert W. Baird | Outperform |
Dec-11-23 | Initiated | TD Cowen | Outperform |
Apr-20-23 | Initiated | Morgan Stanley | Overweight |
Aug-22-22 | Downgrade | Goldman | Buy → Neutral |
Jul-07-22 | Initiated | Mizuho | Buy |
Jun-14-22 | Initiated | UBS | Buy |
Apr-22-22 | Initiated | Piper Sandler | Neutral |
Feb-16-22 | Initiated | Goldman | Buy |
Sep-23-21 | Initiated | Needham | Buy |
Dec-15-20 | Initiated | BofA Securities | Buy |
Dec-10-20 | Initiated | Goldman | Buy |
Feb-20-20 | Initiated | Evercore ISI | Outperform |
Jan-31-20 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-24-19 | Reiterated | Canaccord Genuity | Buy |
Aug-12-19 | Initiated | Jefferies | Buy |
Feb-26-18 | Initiated | JP Morgan | Overweight |
Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
Dec-15-17 | Initiated | Canaccord Genuity | Buy |
Nov-08-17 | Upgrade | SunTrust | Hold → Buy |
Sep-07-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
Aug-30-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Aug-24-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
Aug-23-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
May-02-17 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
May-02-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
May-01-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
Sep-29-16 | Reiterated | RBC Capital Mkts | Outperform |
Sep-29-16 | Downgrade | SunTrust | Buy → Neutral |
View All
Intra Cellular Therapies Inc Stock (ITCI) Latest News
Intra-Cellular Therapies (NASDAQ:ITCI) Lifted to Overweight at Piper Sandler - MarketBeat
Expert Ratings For Intra-Cellular Therapies - Benzinga
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report? - Yahoo Finance
Intra-Cellular Therapies (NASDAQ:ITCI) Shares Gap Up to $72.42 - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Bank of New York Mellon Corp - MarketBeat
Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now - MSN
Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now - Insider Monkey
Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now - Yahoo Finance
How To Trade (ITCI) - Stock Traders Daily
Peaking Back In On Intra-Cellular Therapies (NASDAQ:ITCI) - Seeking Alpha
8,018 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by Maryland State Retirement & Pension System - MarketBeat
10 Best Mid-Cap Healthcare Stocks To Buy Now - Insider Monkey
Allspring Global Investments Holdings LLC Increases Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Privium Fund Management B.V. Has $8.09 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Breakeven? - Simply Wall St
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates Sells 34,396 Shares - MarketBeat
Intra-Cellular Therapies CEO sells over $5 million in company stock - Investing.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
Intra-Cellular Therapies CEO sells over $7m in stock By Investing.com - Investing.com Australia
Raymond James Trust N.A. Sells 194 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Intra-Cellular Therapies CEO sells over $7m in stock - Investing.com
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences - Markets Insider
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences - GlobeNewswire
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences - Yahoo Finance
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sells $2,980,946.54 in Stock - MarketBeat
Legato Capital Management LLC Purchases 9,923 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Calamos Advisors LLC - Defense World
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Calamos Advisors LLC - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Decreased by Nisa Investment Advisors LLC - Defense World
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates Sells 28,680 Shares of Stock - Defense World
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates Sells 53,013 Shares of Stock - Defense World
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates Sells 28,680 Shares - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Envestnet Portfolio Solutions Inc. - Defense World
Intra-Cellular Therapies (NASDAQ:ITCI) Given New $81.00 Price Target at JPMorgan Chase & Co. - Defense World
Intra-Cellular Therapies (NASDAQ:ITCI) PT Raised to $81.00 at JPMorgan Chase & Co. - MarketBeat
Intra-Cellular Therapies executive sells over $1.4m in stock By Investing.com - Investing.com Australia
Weekly Research Analysts’ Ratings Changes for Intra-Cellular Therapies (ITCI) - Defense World
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Mark Neumann Sells 18,714 Shares - Defense World
Intra-Cellular Therapies executive sells over $1.4m in stock - Investing.com India
Intra-Cellular Therapies executive sells over $1.4m in stock By Investing.com - Investing.com Canada
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Sells $1,405,047.12 in Stock - MarketBeat
Intra-Cellular Therapies executive sells over $1.4m in stock By Investing.com - Investing.com UK
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Cwm LLC - Defense World
Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation - Yahoo Finance
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Significant Decrease in Short Interest - Defense World
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Significant Decline in Short Interest - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Assenagon Asset Management S.A. Reduces Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Oak Ridge Investments LLC Invests $811,000 in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Financial Review: Prelude Therapeutics (NASDAQ:PRLD) and Intra-Cellular Therapies (NASDAQ:ITCI) - Defense World
Intra Cellular Therapies Inc Stock (ITCI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Intra Cellular Therapies Inc Stock (ITCI) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Mates Sharon | Chairman and CEO |
Aug 29 '24 |
Option Exercise |
12.73 |
35,604 |
453,239 |
1,105,933 |
Mates Sharon | Chairman and CEO |
Aug 30 '24 |
Option Exercise |
12.73 |
34,396 |
437,861 |
1,104,725 |
Mates Sharon | Chairman and CEO |
Aug 29 '24 |
Sale |
72.57 |
35,604 |
2,583,884 |
1,070,329 |
Mates Sharon | Chairman and CEO |
Aug 30 '24 |
Sale |
72.84 |
34,396 |
2,505,351 |
1,070,329 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):